NASDAQ:URGN Urogen Pharma (URGN) Stock Price, News & Analysis $19.40 +0.34 (+1.78%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$19.44 +0.04 (+0.21%) As of 08/1/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Urogen Pharma Stock (NASDAQ:URGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Urogen Pharma alerts:Sign Up Key Stats Today's Range$18.48▼$19.5850-Day Range$3.93▼$19.4052-Week Range$3.42▼$19.74Volume1.01 million shsAverage Volume1.24 million shsMarket Capitalization$896.28 millionP/E RatioN/ADividend YieldN/APrice Target$32.86Consensus RatingBuy Company Overview UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Read More Urogen Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreURGN MarketRank™: Urogen Pharma scored higher than 92% of companies evaluated by MarketBeat, and ranked 77th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingUrogen Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUrogen Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Urogen Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Urogen Pharma are expected to decrease in the coming year, from ($3.12) to ($3.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Urogen Pharma is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Urogen Pharma is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Urogen Pharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.78% of the outstanding shares of Urogen Pharma have been sold short.Short Interest Ratio / Days to CoverUrogen Pharma has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Urogen Pharma has recently decreased by 60.57%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUrogen Pharma does not currently pay a dividend.Dividend GrowthUrogen Pharma does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.33 Percentage of Shares Shorted15.78% of the outstanding shares of Urogen Pharma have been sold short.Short Interest Ratio / Days to CoverUrogen Pharma has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Urogen Pharma has recently decreased by 60.57%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.47 News SentimentUrogen Pharma has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Urogen Pharma this week, compared to 7 articles on an average week.Search InterestOnly 14 people have searched for URGN on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat Follows13 people have added Urogen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 225% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Urogen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $280,567.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Urogen Pharma is held by insiders.Percentage Held by Institutions91.29% of the stock of Urogen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Urogen Pharma's insider trading history. Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Urogen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Stock News HeadlinesInsider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells 5,149 Shares of StockJuly 31 at 6:37 AM | insidertrades.com3 Bullish Biotech Stocks With Explosive Growth Trends (URGN)These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies...July 21, 2025 | marketbeat.comEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to unlock federal lands, oil reserves, and buried minerals... all for profit. Trump's team is already executing the orders... and Wall Street legend Whitney Tilson is stepping forward to show you how to position before the deadline. | Stansberry Research (Ad)UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025July 29, 2025 | globenewswire.comUroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical OncologyJuly 29, 2025 | finance.yahoo.comUROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action LawsuitJuly 28, 2025 | globenewswire.comUroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in UrologyJuly 28, 2025 | globenewswire.comUROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action LawsuitJuly 21, 2025 | globenewswire.comSee More Headlines URGN Stock Analysis - Frequently Asked Questions How have URGN shares performed this year? Urogen Pharma's stock was trading at $10.65 at the beginning of the year. Since then, URGN shares have increased by 82.2% and is now trading at $19.40. How were Urogen Pharma's earnings last quarter? Urogen Pharma (NASDAQ:URGN) released its earnings results on Monday, May, 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by $0.09. The firm earned $20.25 million during the quarter, compared to the consensus estimate of $22.71 million. Urogen Pharma had a negative trailing twelve-month return on equity of 97,487.15% and a negative net margin of 150.68%. Read the conference call transcript. When did Urogen Pharma IPO? Urogen Pharma (URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. Who are Urogen Pharma's major shareholders? Top institutional investors of Urogen Pharma include ARK Investment Management LLC (0.36%), Oak Ridge Investments LLC (0.15%), Bender Robert & Associates (0.08%) and Truist Financial Corp (0.07%). Insiders that own company stock include Mark Schoenberg and Jason Drew Smith. View institutional ownership trends. How do I buy shares of Urogen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Urogen Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Urogen Pharma investors own include Voyager Therapeutics (VYGR), AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/12/2025Today8/02/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:URGN CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Price Target for Urogen Pharma$32.86 High Price Target$50.00 Low Price Target$16.00 Potential Upside/Downside+69.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($3.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$126.87 million Net Margins-150.68% Pretax Margin-147.23% Return on Equity-97,487.15% Return on Assets-49.57% Debt Debt-to-Equity RatioN/A Current Ratio5.65 Quick Ratio5.47 Sales & Book Value Annual Sales$90.40 million Price / Sales9.91 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / Book-92.38Miscellaneous Outstanding Shares46,200,000Free Float43,845,000Market Cap$896.28 million OptionableOptionable Beta1.12 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:URGN) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.